… resistance to erlotinib has been observed in an NSCLC wild-type cell line (… study in patients
with recurrent NSCLC evaluating onartuzumab plus erlotinib versus placebo plus erlotinib…

… Because the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib …
-cell lung cancer (NSCLC), empirical combinations of these drugs are being tested. This study …

… an increase in lung cancer mortality was observed … studies have also reported an increase
in lung cancer mortality from combined hormone use, and increased incidence of lung cancer …

… 1:1 to erlotinib or docetaxel by the … erlotinib and docetaxel, respectively, based on data
from previous clinical trials. The present study was designed to assess the efficacy of erlotinib …

… The phase III IUNO trial assessed the benefit of maintenance erlotinib versus erlotinib at
progression in advanced/metastatic non-small-cell lung cancer (NSCLC) that had not …

… non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib would be efficacious in
… In conclusion, this study did not show a DFS benefit for erlotinib in patients with IHC- or FISH…

… studies determining the erlotinib concentration in these patients is limited. The purpose of this
study was to measure the concentration of erlotinib … ‑small‑cell lung carcinoma. Six patients …

… Erlotinib-related rash was observed in 70% of pts: the majority (83… from the BR.21 study and
confirm that erlotinib is an effective and … biomarkers for erlotinib will be presented separately. …

… The primary objective of this open-label, nonrandomized phase II study was to prospectively
… treated with erlotinib until disease progression. Exploratory endpoints of this study included …

… with squamous cell histology. Male ever-smokers with … cell non–small-cell lung cancer
derived a significant survival benefit from erlotinib (HR, 0.66; P = 0.015) despite a very low tumor …